Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.

Filipe A Moura,David D Berg,Andrea Bellavia,Jamie P Dwyer,Ofri Mosenzon,Benjamin M Scirica,Stephen D Wiviott,Deepak L Bhatt,Itamar Raz,Mark W Feinberg,Eugene Braunwald,David A Morrow,Marc S Sabatine

Diabetes care（2023）

引用 0|浏览45

暂无评分

摘要

Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition.

查看译文

关键词

sglt2 inhibition,kidney disease progression,diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要